Transparency Bill Reintroduced in Oregon

During the 2017 Oregon Legislature session, Senator Steiner Hayward and Representative Rob Nosse introduced legislation on prescription drug advertising that would have required manufacturers to disclose prices in any advertisement for prescription drugs in Oregon. The bill was introduced on February 14, 2017 and was referred to the Health Care Committee. On March 9, 2017, the Health Care Committee held a public hearing, but when the legislature adjourned on July 7, 2017, the bill remained in Committee, and therefore, it died on the vine. On January 22, 2018, Representative Nosse introduced HB 4005, “Prescription Drug Price Transparency Act,” a supposedly simplified version of the 2017 price transparency bill. The bill, which is expected to be officially introduced on February 5, 2018, requires prescription drug manufacturers to annually report information to the Department of Consumer and Business Services regarding the prices of prescription drugs and the costs associated with developing and marketing prescription drugs. It also authorizes the Department to impose civil penalties on manufacturers that fail to comply with reporting requirements. Under the language of the bill, manufacturers would have to justify the price of any prescription drug that goes up ten percent or more over a calendar year if the monthly cost is over $100. The proposal would also require manufacturers to report on new specialty drugs that have price tags of $600 or more per month/dosage and ...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs